Search > Non-Small Cell Lung Cancer
My employer runs this trial

Pumitamig-Based Therapy for Non-Small Cell Lung Cancer

Not yet recruiting at 49 trial locations
Fl
Overseen ByFirst line of the email MUST contain NCT # and Site #.
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Bristol-Myers Squibb
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to assess the safety, tolerability, and surgical feasibility of preoperative Pumitamig-based therapy and other molecules in resectable, Early-Stage Non-Small Cell Lung Cancer

Who Is on the Research Team?

BS

Bristol-Myers Squibb

Principal Investigator

Bristol-Myers Squibb

Are You a Good Fit for This Trial?

This trial is for adults with early-stage non-small cell lung cancer that can be removed by surgery. Participants should be healthy enough for both the treatment and surgery, and must not have other serious health issues or cancers.

Inclusion Criteria

I am fully active or restricted in physically strenuous activity only.
I have newly diagnosed, untreated, resectable Stage IIA-IIIB NSCLC.
My cancer has been tested for PD-L1 expression.

Exclusion Criteria

I do not have any active autoimmune diseases.
I do not have serious or uncontrolled heart or blood vessel problems.
Other protocol-defined Inclusion/Exclusion criteria apply
See 5 more

What Are the Treatments Tested in This Trial?

Interventions

  • Carboplatin
  • Cisplatin
  • Paclitaxel
  • Pemetrexed
  • Pumitamig

Trial Overview

The study tests a new drug called Pumitamig given before surgery, along with standard chemotherapy drugs (carboplatin, cisplatin, paclitaxel, pemetrexed), to see if this combination is safe and doable before removing the tumor.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: Cohort B: PumitamigExperimental Treatment5 Interventions
Group II: Cohort A: PumitamigExperimental Treatment5 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Bristol-Myers Squibb

Lead Sponsor

Trials
2,731
Recruited
4,127,000+
Headquarters
New York City, USA
Known For
Oncology & Cardiovascular
Top Products
Eliquis, Opdivo, Revlimid, Orencia
Christopher Boerner profile image

Christopher Boerner

Bristol-Myers Squibb

Chief Executive Officer since 2023

PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis

Deepak L. Bhatt profile image

Deepak L. Bhatt

Bristol-Myers Squibb

Chief Medical Officer since 2024

MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania

BioNTech SE

Industry Sponsor

Trials
84
Recruited
120,000+

Prof. Dr. Ugur Sahin

BioNTech SE

Chief Executive Officer since 2008

MD from University of Cologne

Prof. Özlem Türeci

BioNTech SE

Chief Medical Officer since 2018

MD from Saarland University

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.